Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02124148
Title A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Eli Lilly and Company
Indications

breast cancer

Advanced Solid Tumor

colorectal cancer

Therapies

Cisplatin + Prexasertib

Cetuximab + Prexasertib

Pemetrexed Disodium + Prexasertib

LY3023414 + Prexasertib

Fluorouracil + Leucovorin + Prexasertib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Florida Cancer Specialists Sarasota Florida 34232 United States Details
University of Oklahoma Health Sciences Center Oklahoma City Oklahoma 73104 United States Details
Sarah Cannon Research Institute SCRI Nashville Tennessee 37203 United States Details
Tennessee Oncology PLLC Nashville Tennessee 37203 United States Details
University of Texas MD Anderson Cancer Center Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field